Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report

  • Maria de Fátima Borges Universidade Federal do Triângulo Mineiro; Divisão de Endocrinologia e Metabolismo
  • Beatriz Hallal Jorge Lara Universidade Federal do Triângulo Mineiro; Divisão de Endocrinologia e Metabolismo
  • Janaíne Machado Tomé Universidade Federal do Triângulo Mineiro; Divisão de Endocrinologia e Metabolismo
  • Leopoldo Prezia de Araújo Universidade Federal do Triângulo Mineiro; Divisão de Neurocirurgia
  • Flávio Cesar Lucas Bugiga Universidade Federal do Triângulo Mineiro; Divisão de Endocrinologia e Metabolismo
  • Júlio Cláudio Sousa Universidade Federal do Triângulo Mineiro; Divisão de Otorrinolaringologia
  • Jacqueline Mendes Fonseca Soares Universidade Federal do Triângulo Mineiro; Divisão de Endocrinologia e Metabolismo
  • Roberto Alexandre Dezena Universidade Federal do Triângulo Mineiro; Divisão de Neurocirurgia
  • Beatriz Pires Ferreira Universidade Federal do Triângulo Mineiro; Divisão de Endocrinologia e Metabolismo
Keywords: Acromegaly, Gigantism, Treatment, Outcome

Abstract

OBJECTIVE: To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro. METHODS: Cross-sectional and retrospective study of thirty cases treated over a period of two decades. RESULTS: 17 men (56.7%) aged 14-67 years and 13 women aged 14-86 years were analyzed. Twenty-one patients underwent transphenoidal surgery, whichwas associated with somatostatin receptor ligands in 11 patients (39.3%), somatostatin receptor ligands + radiotherapyin 5 patients (17.8%), radiotherapy in 3 patients (10.7%), and radiotherapy + somatostatin receptorligands + cabergoline in 1 patient (3.6%). Additionally, 2 patients underwent radiotherapy and surgeryalone. Six patients received somatostatin receptor ligands before surgery, and 2 were not treated due to refusal and death. Nine patients have died, and 20 are being followed; 13 (65%) have growth hormonelevels o1 ng/mL, and 11 have normal insulin-like growth factor 1 levels. CONCLUSION: The current treatment options enable patients seen in regional reference centers to achieve strict control parameters, which allows them to be treated close to their homes.

Downloads

Download data is not yet available.
Published
2017-04-01
How to Cite
de Fátima Borges, M., Lara, B., Tomé, J., de Araújo, L., Bugiga, F., Sousa, J., Soares, J., Dezena, R., & Ferreira, B. (2017). Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report. Clinics, 72(4), 218-223. https://doi.org/10.6061/clinics/2017(04)05
Section
Clinical Sciences